TY - JOUR
T1 - Survival patterns in lung and pleural cancer in Europe 1999-2007
T2 - Results from the EUROCARE-5 study
AU - Francisci, Silvia
AU - Minicozzi, Pamela
AU - Pierannunzio, Daniela
AU - Ardanaz, Eva
AU - Eberle, Andrea
AU - Grimsrud, Tom K.
AU - Knijn, Arnold
AU - Pastorino, Ugo
AU - Salmerón, Diego
AU - Trama, Annalisa
AU - Sant, Milena
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Background Survival of patients diagnosed with lung and pleura cancer is a relevant health care indicator which is related to the availability and access to early diagnosis and treatment facilities. Aim of this paper is to update lung and pleural cancer survival patterns and time trends in Europe using the EUROCARE-5 database. Methods Data on adults diagnosed with lung and pleural cancer from 87 European cancer registries in 28 countries were analysed. Relative survival (RS) in 2000-2007 by country/region, age and gender, and over time trends in 1999-2007 were estimated. Results Lung cancer survival is poor everywhere in Europe, with a RS of 39% and 13% at 1 and 5 years since diagnosis, respectively. A geographical variability is present across European areas with a maximum regional difference of 12 and 5 percentage points in 1-year and 5-year RS respectively. Pleural cancer represents 4% of cases included in the present study with 7% 5-year RS overall in Europe. Most pleural cancers (83%) are microscopically verified mesotheliomas. Survival for both cancers decreases with advancing age at diagnosis for both cancers. Slight increasing trends are described for lung cancer. Survival over time is higher for squamous cell carcinoma and adenocarcinomas than for small and large cell carcinoma; and better among women than men. Conclusions Despite the generalised although slight increase, survival of lung and pleural cancer patients still remains poor in European countries. Priority should be given to prevention, with tobacco control policies across Europe for lung cancer and banning asbestos exposure for pleural cancer, and in early diagnosis and better treatment. The management of mesothelioma needs a multidisciplinary team and standardised health care strategies.
AB - Background Survival of patients diagnosed with lung and pleura cancer is a relevant health care indicator which is related to the availability and access to early diagnosis and treatment facilities. Aim of this paper is to update lung and pleural cancer survival patterns and time trends in Europe using the EUROCARE-5 database. Methods Data on adults diagnosed with lung and pleural cancer from 87 European cancer registries in 28 countries were analysed. Relative survival (RS) in 2000-2007 by country/region, age and gender, and over time trends in 1999-2007 were estimated. Results Lung cancer survival is poor everywhere in Europe, with a RS of 39% and 13% at 1 and 5 years since diagnosis, respectively. A geographical variability is present across European areas with a maximum regional difference of 12 and 5 percentage points in 1-year and 5-year RS respectively. Pleural cancer represents 4% of cases included in the present study with 7% 5-year RS overall in Europe. Most pleural cancers (83%) are microscopically verified mesotheliomas. Survival for both cancers decreases with advancing age at diagnosis for both cancers. Slight increasing trends are described for lung cancer. Survival over time is higher for squamous cell carcinoma and adenocarcinomas than for small and large cell carcinoma; and better among women than men. Conclusions Despite the generalised although slight increase, survival of lung and pleural cancer patients still remains poor in European countries. Priority should be given to prevention, with tobacco control policies across Europe for lung cancer and banning asbestos exposure for pleural cancer, and in early diagnosis and better treatment. The management of mesothelioma needs a multidisciplinary team and standardised health care strategies.
KW - Europe
KW - Lung cancer
KW - Morphology
KW - Pleural cancer
KW - Population-based cancer registries
KW - Survival trends
UR - http://www.scopus.com/inward/record.url?scp=84942416855&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942416855&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2015.07.033
DO - 10.1016/j.ejca.2015.07.033
M3 - Article
AN - SCOPUS:84942416855
VL - 51
SP - 2242
EP - 2253
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 15
ER -